Stocks Health care SRTA
NASDAQ · Health careStrata Critical Medical, Inc. (SRTA)
Strata Critical Medical, Inc. brought in $280.8M of revenue over the twelve months to September 30, 2026, up 130.8% from a year earlier. It posted a net loss of $24.8M. In fiscal 2025 capital spending exceeded operating cash flow by $58.5M. At September 30, 2026 it held $35.1M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 3, 2026.
Key facts about Strata Critical Medical, Inc.
- Net worth
- Strata Critical Medical, Inc. has a market value (market cap) of $535.2M at the latest share price, and shareholders' equity of $276.4M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $197.1M (+34.3% year on year), with net income of $41.3M. Over the 12 months to September 30, 2026: revenue $280.8M, net loss $24.8M.
- Cash flow
- In fiscal 2025 operations used $48.9M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 3, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Strata Critical Medical, Inc.'s next report is expected around March 2, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Strata Critical Medical, Inc. does
Strata Critical Medical, Inc. is registered with the SEC under industry code SIC 4700 (Transportation Services). Its shares trade on NASDAQ under the ticker SRTA.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $197.1M | $41.3M | $0.50 | -$58.5M |
| 2024 | $146.8M | -$27.3M | -$0.35 | -$33.4M |
| 2023 | $225.2M | -$56.1M | -$0.76 | -$34.5M |
| 2022 | $146.1M | -$27.3M | -$0.38 | -$37.9M |
| 2021 | $50.5M | -$40.1M | -$0.93 | -$15.9M |
| 2020 | n/a | -$20.5M | -$2.17 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where SRTA ranks in Health care
Latest SEC filings
What Strata Critical Medical, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 3, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 50% to $74.1M versus the same quarter last year; diluted EPS -$0.09 versus $0.70.
- November 3, 2026
- October 15, 2026Activist stake (5% or more) SCHEDULE 13D
- August 20, 2026Passive stake changed SCHEDULE 13G/A
- August 4, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 61% to $72.5M versus the same quarter last year; diluted EPS -$0.12 versus -$0.05.
- August 4, 2026
- July 8, 2026Passive stake changed SCHEDULE 13G/A
- June 17, 2026Passive stake (5% or more) SCHEDULE 13G
- June 3, 2026
- May 8, 2026Activist stake changed SCHEDULE 13D/A
Insider trades
What the people running Strata Critical Medical, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $10K worth of shares on the open market in the last 90 days and sold none.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 5, 2026 | Lauck AndrewDirector | Bought | 2,000 | $10K |
| October 28, 2026 | Wunsch Scott MCEO, Logistics | Received as pay | 57,173 | - |
| October 28, 2026 | Wunsch Scott MCEO, Logistics | Received as pay | 57,173 | - |
| October 28, 2026 | Wunsch Scott MCEO, Logistics | Received as pay | 1,416 | - |
| October 28, 2026 | Wunsch Scott MCEO, Logistics | Shares withheld for tax | 44,996 | $214.2K |
| September 24, 2026 | Heyburn William A.Co-CEO and CFO, Director | Received as pay | 177,858 | - |
| September 24, 2026 | Heyburn William A.Co-CEO and CFO, Director | Shares withheld for tax | 98,356 | $518.3K |
| September 24, 2026 | Tomkiel Melissa M.Co-CEO and General Counsel, Director | Received as pay | 177,858 | - |
Who owns SRTA
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Steele ExpCo Holdings, LLC13G, passive with 2 related filers | 9% | August 20, 2026 |
| Third Point LLC13D, may seek influence with 1 related filers | 5.8% | October 15, 2026 |
| Northern Right Capital Management, L.P.13G, passive with 5 related filers | 5.1% | June 17, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 139 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Third Point LLC | 5,000,000 | 0 |
| Northern Right Capital Management, L.P. | 4,890,584 | +800,415 |
| BlackRock, Inc. | 4,835,516 | +267,248 |
| First Eagle Investment Management, LLC | 4,629,228 | +2,362,985 |
| Royce & Associates LP | 3,132,933 | +316,561 |
| Vanguard Capital Management LLC | 2,885,319 | +12,873 |
| AWM Investment Company, Inc. | 2,821,468 | 0 |
| ARK Investment Management LLC | 2,730,855 | -4,724,429 |
| Pillsbury Lake Capital LLC | 2,171,006 | -432,790 |
| Geode Capital Management, LLC | 1,755,383 | +55,673 |
| Dimensional Fund Advisors LP | 1,738,623 | +121,519 |
| State Street Corp | 1,524,390 | +178,315 |
| Uniplan Investment Counsel, Inc. | 1,429,514 | +129,197 |
| Bank of New York Mellon Corp | 1,141,035 | +62,010 |
| Sumitomo Mitsui Trust Group, Inc. | 1,052,611 | -601,750 |
| Amova Asset Management Americas, Inc. | 989,100 | -665,261 |
| Northern Trust Corp | 676,575 | +32,940 |
| Creek Drive Management Group LLC | 586,200 | -473,800 |
| Citigroup Inc | 526,859 | +430,224 |
| Vanguard Portfolio Management LLC | 526,143 | +42,723 |
Insiders
10 insiders reported holding 11,971,060 shares in total, about $72.4M at the last price.
| Holder | Shares |
|---|---|
| Wiesenthal Robert SDirector | 5,325,896 |
| Tomkiel Melissa M.Co-CEO and General Counsel, Director | 2,153,678 |
| Heyburn William A.Co-CEO and CFO, Director | 1,757,850 |
| Verdetto Louis R.CEO, Clinical Services | 1,128,096 |
| Wunsch Scott MCEO, Logistics | 746,254 |
| Philip Edward MDirector | 265,078 |
| Cohen AmirChief Accounting Officer | 177,154 |
| Lauck AndrewDirector | 172,902 |
| Love ReginaldDirector | 146,481 |
| Cook William L. IIIDirector | 97,671 |
Questions about SRTA
What does Strata Critical Medical, Inc. do?
Strata Critical Medical, Inc. is a company in the Health care sector, listed on NASDAQ as SRTA. Its shares trade on NASDAQ under the ticker SRTA.
What is Strata Critical Medical, Inc.'s net worth?
Strata Critical Medical, Inc. has a market value (market cap) of $535.2M at the latest share price, and shareholders' equity of $276.4M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Strata Critical Medical, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $24.8M on revenue of $280.8M.
How much revenue does Strata Critical Medical, Inc. make?
Over the twelve months to September 30, 2026 Strata Critical Medical, Inc. reported revenue of $280.8M. That is 130.8% more than a year earlier.
When did Strata Critical Medical, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 3, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the insider trade from November 9, 2026.
When is Strata Critical Medical, Inc.'s next earnings report?
Strata Critical Medical, Inc.'s next report is expected around March 2, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare SRTA with
Follow SRTA
Get an email when Strata Critical Medical, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Strata Critical Medical, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.